New hope for tough blood cancers? early trial launches
NCT ID NCT06037018
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage study is testing a new biologic drug called CC312 in 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to standard treatments. The main goals are to check safety and find the right dose. Participants receive CC312 by IV infusion, and researchers will monitor side effects and how the drug behaves in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CC312 (a biologic drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for people with certain blood cancers that have not responded to other therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 44 participants, so the main goal is safety, not effectiveness. The drug may not work or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
InstituteHBDH
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike
- Can donor immune cells be engineered to fight blood cancer?